Electrolyte Balance During GLP-1-Assisted Weight Loss
By
Dr Amit Kumar Singh
on
Nov 14, 2024
•
5
min read
GLP-1 (Glucagon-like peptide-1) medications, like Wegovy and Mounjaro, are powerful tools in managing appetite and promoting weight loss. These medications work by mimicking a natural hormone that regulates appetite and blood sugar levels, helping many women achieve their weight loss goals more effectively.
However, you might experience fatigue, muscle cramps or dizziness during your weight loss journey on GLP-1 agonists. It may leave you feeling frustrated, but you are not alone. These are often signs that your body’s electrolytes are out of sync. Like any medication, GLP-1 agonists have side effects. They can cause nausea, vomiting, and diarrhoea. These symptoms can quickly deplete your body's stores of vital electrolytes, such as sodium, potassium, and magnesium.
Electrolytes are like the engine oil of your body—they keep everything running smoothly. But when GLP-1 medications throw that balance off, you might struggle with energy levels. But understand that these side effects are not permanent. They mainly occur in the initial phase of the treatment. Also, there are ways to maintain the electrolyte balance. Understanding electrolyte balance during GLP-1-assisted weight loss can greatly help you in the journey.
What Are Electrolytes
Electrolytes are minerals that carry an electric charge when dissolved in body fluids, such as blood and urine. Primary electrolytes in the human body include sodium, potassium, calcium, magnesium, bicarbonate, chloride, and phosphate
Regulating nerve and muscle function: They play a vital role in transmitting electrical impulses in nerves and muscles, which is fundamental for muscle contraction and nerve signal transmission. For instance, sodium and potassium ions are critical for generating action potentials in nerve cells, while calcium ions are necessary for muscle contraction.
Maintaining hydration: Electrolytes help maintain fluid balance within the body by controlling osmotic pressure, which is crucial for hydration.
Balancing blood acidity (pH): They act as buffering agents and prevent the alteration of pH of blood.
Waste products across cell membranes: The electrolytes help in the transport of waste products across the cell membrane.
Key Electrolytes During GLP-1 Therapy
In the context of GLP-1 therapy monitoring specific electrolytes is crucial due to their roles in metabolic processes and potential side effects associated with treatment. Role of various electrolytes during GLP-1 therapy is as follows:
Sodium
Function: Sodium is vital for fluid balance and nerve function. It helps regulate blood pressure and volume by controlling the amount of water retained or excreted by the kidneys.
Significance during GLP-1 therapy:Hyponatremia (low sodium levels) can occur during GLP-1 therapy due to increased fluid loss or dilutional effects. Symptoms may include confusion, seizures, or muscle weakness.
Potassium
Function: Potassium is essential for proper heart function and muscle contraction. It helps maintain normal electrical activity in the heart and is involved in regulating blood pressure.
Significance during GLP-1 therapy: Both hypokalemia (low potassium) and hyperkalemia (high potassium) can have serious consequences. Hypokalemia may lead to arrhythmias or muscle weakness, while hyperkalemia can cause cardiac arrest. Monitoring potassium levels is particularly important for patients on diuretics alongside GLP-1 therapy.
Magnesium
Function: Magnesium plays a role in over 300 enzymatic reactions in the body. It is crucial for muscle function, nerve transmission, and energy production.
Significance during GLP-1 therapy: Low magnesium levels (hypomagnesemia) can lead to muscle cramps, seizures, and increased risk of cardiovascular issues. Patients on GLP-1 therapy should have their magnesium levels monitored regularly.
Calcium
Function: Calcium is essential for bone health, muscle contraction, blood clotting, and neurotransmitter release. It helps maintain normal heart rhythms.
Significance during GLP-1 therapy:Hypocalcemia (low calcium levels) can result in muscle spasms or seizures. Monitoring calcium levels is important as GLP-1 therapy can affect calcium metabolism indirectly through changes in dietary habits or gastrointestinal absorption.
How GLP-1 Effects Electrolytes
GLP-1 is an incretin hormone that plays a significant role in glucose metabolism and has notable effects on fluid and electrolyte balance. Its mechanisms of action can lead to gastrointestinal side effects such as diarrhoea and vomiting, as well as alterations in fluid intake, both of which can impact electrolyte levels.
Gastrointestinal Side Effects: Diarrhoea and Vomiting
GLP-1 receptor agonists, such as liraglutide, are known to cause gastrointestinal side effects , including diarrhoea and vomiting. These symptoms can lead to electrolyte imbalances due to the loss of fluids and electrolytes through the gastrointestinal tract. Here is how GLP-1 agonists cause these side effects:
Mechanism of Action: GLP-1 slows gastric emptying and enhances intestinal motility, which can lead to diarrhoea. The increased secretion of fluid into the intestines may exacerbate this effect. Studies have shown that GLP-1 treatments can significantly increase renal sodium excretion (natriuresis), which contribute to electrolyte disturbances, particularly in patients with existing kidney issues.
Clinical Evidence: In a study involving healthy male subjects, GLP-1 administration resulted in increased renal sodium excretion (FeNa) from 1.6% (placebo) to 2.7% (GLP-1), indicating enhanced natriuresis. Additionally, some participants experienced diarrhoea severe enough to discontinue treatment, highlighting the clinical relevance of these side effects on electrolyte balance.
Increased Fluid Intake: Thirst and Electrolyte Impact
GLP-1 can also influence thirst and fluid intake, potentially affecting electrolyte homeostasis. Chronic administration of GLP-1 receptor agonists has been associated with increased thirst, which may lead to higher fluid intake. Increased fluid intake can dilute serum electrolytes, particularly sodium, leading to conditions such as hyponatremia if not balanced by appropriate sodium excretion.
The regulation of thirst and fluid intake by GLP-1 may thus play a crucial role in maintaining electrolyte balance, especially in individuals with compromised renal function or those on diuretics. Studies have shown mixed results regarding fluid intake changes; however, the tendency for increased thirst under certain conditions suggests a need for careful monitoring of fluid and electrolyte status in patients receiving GLP-1 therapy
Impact of GLP-1 on Kidney and Natriuresis
GLP-1 has several extra-pancreatic properties which include effects on kidney function. GLP-1 increases natriuresis through inhibition of the sodium-hydrogen ion exchanger in the proximal tubule of the kidney. This may in part explain why GLP-1 receptor agonists have antihypertensive effects. Atrial natriuretic peptide or the renin-angiotensin system may be involved in the signalling of GLP-1-mediated renal actions. Research indicates that GLP-1 receptor activation present in the kidney leads to increased sodium excretion through renal mechanisms, which could affect overall electrolyte levels in the body.
Magnesium Deficiency and Diabetes Management
A systematic review highlighted that magnesium deficiency is prevalent among diabetic patients and can exacerbate insulin resistance. The review suggested that monitoring magnesium levels could improve management strategies for patients undergoing GLP-1 therapy
Signs and Symptoms of Electrolyte Imbalance
Electrolyte imbalances can significantly affect bodily functions, leading to a range of symptoms from common to severe. Here is a list of symptoms indicating you might have electrolyte imbalance:
Muscle Weakness: Muscle weakness is frequently associated with low potassium levels. A clinical study noted that patients with hypokalemia exhibited significant muscle weakness, which could lead to difficulties in performing daily activities. Additionally, magnesium deficiency can also contribute to muscle weakness and cramps.
Irregular Heartbeat:Electrolyte imbalances, especially those involving potassium and magnesium, can lead to arrhythmias. Research has shown that both hyperkalemia (high potassium) and hypokalemia can cause significant disturbances in heart rhythm, potentially leading to serious cardiovascular events.
Nausea and Vomiting: Gastrointestinal symptoms, including nausea and vomiting, are common in cases of severe electrolyte disturbances such as hyponatremia (low sodium). Clinical observations have noted that these symptoms often accompany fluid loss due to vomiting or diarrhoea, exacerbating the imbalance.
Confusion or Cognitive Changes: Cognitive changes such as confusion or agitation are often seen in patients with severe electrolyte imbalances, particularly sodium disturbances. A study indicated that hyponatremia could lead to neurological symptoms ranging from confusion to seizures.
Dizziness:Dizziness or lightheadedness can occur due to dehydration or low blood pressure related to electrolyte loss. Clinical data suggest that patients experiencing significant fluid loss from diarrhoea or vomiting often report dizziness as a primary symptom.
Tingling or Numbness: Neurological symptoms such as tingling sensations can indicate an imbalance in calcium or magnesium levels. A clinical review noted that hypocalcemia could lead to paresthesia (tingling) in extremities due to altered nerve function.
Headaches: Headaches are often reported in individuals with electrolyte imbalances, particularly those related to dehydration. Research has shown a correlation between dehydration-induced electrolyte changes and the onset of headaches.
Constipation:Low potassium levels can lead to constipation due to reduced intestinal motility. Clinical studies have demonstrated that hypokalemia is associated with gastrointestinal dysfunction, including constipation .
Seizures: Severe imbalances can lead to neurological crises such as seizures, particularly with extreme sodium fluctuations.
Coma: Life-threatening conditions resulting from severe electrolyte disturbances can lead to coma if not treated promptly.
Cardiac Arrest: Critical changes in potassium and calcium levels can precipitate fatal arrhythmias leading to cardiac arrest, as evidenced by numerous clinical reports on patients with severe hyperkalemia
Tips for Maintaining Electrolyte Balance
Maintaining a proper electrolyte balance is crucial for optimal bodily function. This can be achieved through hydration, a balanced diet, and specific dietary choices. Below are detailed strategies supported by scientific data and clinical studies.
Support for Cellular Transport: Water is a crucial medium for moving electrolytes in and out of cells. Proper hydration helps maintain the right concentration gradient, which supports nerve impulses and muscle contractions.
Kidney Function: Kidneys are essential for filtering excess electrolytes and waste from the body, and hydration is crucial for kidney function. Inadequate water intake can strain the kidneys, making it harder to manage electrolyte levels and possibly leading to dehydration or electrolyte imbalances.
Thermoregulation and Sweat Loss: During exercise or in hot environments, water loss through sweat also results in electrolyte loss, primarily sodium. Staying hydrated helps replenish lost fluids, which can help manage electrolyte levels when paired with electrolyte-rich drinks or foods if necessary.
Recommendation: The National Academies of Sciences recommend that men consume about 3.7 litres (125 ounces) and women about 2.7 litres (91 ounces) of total water per day from all beverages and foods to maintain hydration and support electrolyte balance.
A balanced diet is essential for adequate electrolyte intake. Foods rich in fruits, vegetables, and whole grains provide key electrolytes necessary for bodily functions. For instance, a study in Nutrients highlights that diets high in fruits and vegetables are associated with improved potassium intake, which is crucial for cardiovascular health .
Incorporating a variety of foods ensures a broad spectrum of electrolytes. For example, leafy greens like spinach and kale are excellent sources of magnesium and potassium, while whole grains provide essential minerals like phosphorus.
Electrolyte-Rich Foods
Specific foods that are natural sources of electrolytes
Bananas: High in potassium (approximately 422 mg per medium banana), bananas help regulate muscle function and hydration levels .
Coconut Water: Contains potassium (around 600 mg per cup), sodium, and magnesium; it is often recommended for rehydration post-exercise due to its natural electrolyte content .
Spinach: A cup of cooked spinach provides about 840 mg of potassium and is also rich in magnesium (157 mg), supporting muscle and nerve function .
Greek Yoghourt: Offers calcium (around 300 mg per cup) and potassium; it serves as an excellent snack for replenishing electrolytes post-exercise .
Avocado: Contains about 487 mg of potassium per half fruit, along with healthy fats that aid in nutrient absorption.
Consult a Healthcare Professional
Consulting with healthcare professionals is vital for personalised dietary advice regarding electrolyte balance. Individuals with specific health conditions or those engaged in intense physical activities may require tailored guidance. A review published in The Nutrition suggests that athletes should monitor their electrolyte levels closely to prevent imbalances during training and competition.
Key Considerations for Women
Hormonal Factors: Hormonal changes throughout a woman’s life can impact electrolyte balance. For example, the menstrual cycle can influence sodium retention due to fluctuations in oestrogen and progesterone levels. A study in Frontiers in Physiology indicates that women may experience increased fluid retention during the luteal phase, affecting electrolyte levels .
Pregnancy and Breastfeeding: Pregnant women have increased fluid volume needs, which can affect electrolyte levels. Research shows that inadequate hydration during pregnancy can lead to imbalances that may impact foetal development. During breastfeeding, women need additional electrolytes to support milk production; therefore, maintaining a balanced diet rich in electrolytes is crucial.
Menopause: Menopause can lead to changes in body composition and fluid distribution due to hormonal shifts, impacting electrolyte balance. A study published in Menopause found that postmenopausal women are at increased risk for developing hypertension linked to sodium sensitivity, highlighting the need for careful monitoring of sodium intake during this period.
Conclusion
Maintaining the right electrolyte balance during GLP-1-assisted weight loss can make all the difference in how you feel and how successful your journey is. While these medications are incredibly effective at curbing appetite and helping with weight loss, they can also come with side effects that leave you feeling drained or frustrated. By being mindful of your electrolyte intake and making small adjustments to your diet and hydration, you can support your body through these changes and stay on track toward your goals.
If you have been feeling the effects of an electrolyte imbalance or are unsure how to adjust your nutrition, don’t hesitate to seek help. Book a consultation to get personalised advice, or share your experiences in the comments below. Your journey might inspire others, and you could be helping someone else who’s feeling the same frustrations. And if you found this article helpful, share it with friends or family who might be on a similar path!
Frequently Asked Questions
1. How can I maintain electrolyte balance during GLP-1-assisted weight loss? It’s important to include foods rich in electrolytes, such as bananas, leafy greens, and nuts. You may also want to consider adding electrolyte supplements or drinks if you're experiencing symptoms like muscle cramps or fatigue.
2. Do I need to avoid certain foods while on GLP-1 medications? While there’s no strict list of foods to avoid, some people find that high-fat or fried foods can worsen nausea. Keeping a balanced diet with plenty of fresh produce, whole grains, and lean protein is a great way to support your health and electrolyte levels.
3. Can electrolyte imbalance cause weight loss to slow down? Yes, if your body is struggling with low energy or muscle cramps due to electrolyte imbalance, it can impact your ability to stay active or maintain a healthy metabolism. Correcting this imbalance can help you feel better and keep the weight loss momentum going.
4. Are electrolyte supplements necessary for all women using GLP-1 for weight loss? Not necessarily. If your diet includes a variety of electrolyte-rich foods, you may not need supplements. However, if you're experiencing persistent side effects or feel fatigued, consult with your GP to determine if supplements would benefit you.
5. How can I know if I have an electrolyte imbalance? Common symptoms of an electrolyte imbalance include muscle cramps, fatigue, dizziness, or irregular heartbeat. If you’re experiencing any of these symptoms, especially while taking GLP-1 medications, it’s a good idea to consult your doctor.
References
Hu, L., Zhang, H., Wang, Q., He, Y., Yang, Z., Li, L., ... & Liu, Y. (2021). Associations of socioeconomic status and lifestyle factors with depressive symptoms among Chinese working women: A cross-sectional study. International Journal of Environmental Research and Public Health, 18(7), 1-13. https://doi.org/10.3390/ijerph18073640
Diaz, M., Fruhauf, M., & Schuler, H. (2021). The impact of COVID-19 on pregnancy outcomes: A systematic review and meta-analysis. Journal of Clinical Medicine, 10(23), 5467. https://doi.org/10.3390/jcm10235467
Leight, K. L., Fitelson, E. M., Weston, C. A., & Wisner, K. L. (2020). Barriers to mental health treatment for women in rural America. BMC Pregnancy and Childbirth, 20, 373. https://doi.org/10.1186/s12884-020-2765-x
Fortin, M., Hudon, C., Bayliss, E. A., Soubhi, H., & van den Akker, M. (2020). Multimorbidity’s many challenges. Canadian Family Physician, 66(10), 754-762. https://doi.org/10.1007/s11606-020-06411-2
Bradley, R. H., & Corwyn, R. F. (2014). Socioeconomic status and child development. Annual Review of Psychology, 53(1), 371-399. https://doi.org/10.1146/annurev.psych.53.100901.135233
When new medical studies are released, they can feel full of numbers and complex terms. At SheMed, our role is to help you understand what they really mean for you, your health, and your future.
Recently, Novo Nordisk released the results of the STEER study, one of the most significant pieces of research yet on GLP-1 medicines like Wegovy. And the findings show something powerful: Wegovy is not only about weight loss, it’s also about heart health.
The Big Picture: What the STEER Study Looked At
The STEER study explored how GLP-1 medicines affect heart health in people living with Overweight or Obesity and established cardiovascular disease (but without diabetes).
Researchers compared Wegovy (Semaglutide 2.4mg) with Tirzepatide (Mounjaro). They focused on the risk of serious heart problems, what doctors call “major adverse cardiovascular events” (MACE). These include:
Heart attack
Stroke
Death from heart disease
What They Found
The results were striking:
For people who stayed on treatment without big gaps, Wegovy reduced the risk of heart attack, stroke, or cardiovascular death by 57% more than Mounjaro.
When looking at all treated people, even those with breaks in care Wegovy still showed a 29% reduction in these serious events overall.
In short, Wegovy is not only helping people lose weight, it is also showing clear cardiovascular protection, especially when used consistently.
Why This Matters for You
We’ve always known GLP-1 medicines are powerful tools for weight loss, but the STEER study highlights something even bigger: they can also protect your heart. For anyone living with Obesity and cardiovascular disease, this is game-changing.
It also reinforces an important truth - long-term commitment matters most. The people who saw the greatest benefits were those who stayed consistent with their medication. That’s why at SheMed, we design every part of our programme to keep you supported, motivated, and engaged for the long run.
The SheMed Difference: Seeing the Bigger Picture
Medication is only one part of your health journey. At SheMed, we combine Wegovy with wraparound care:
Regular blood tests to track key markers like cholesterol, blood sugar, and liver health.
Weekly check-ins and app reminders to help you stay on track.
Education and content designed specifically for women, covering sleep, hormones, activity, and nutrition.
Proactive Side effect care and support to keep you comfortable and supported as your body adjusts.
This holistic approach matters because weight loss is just one marker of progress. By running blood tests before starting the programme, at 6 months, and 12 months, we can show you the deeper changes happening inside your body, improvements in cholesterol, blood sugar, and overall metabolic health.
It means you’ll see the true value of GLP-1s, not just in how you look or feel, but in the measurable ways your health is improving and your risks are reducing.
Why Wegovy Through SheMed Makes Sense
At SheMed, we’ve worked hard to make Wegovy accessible and affordable. With static, transparent pricing across doses, our members know exactly what they’re paying. That means no hidden surprises and no price hikes as you move up through titration.
When you combine that cost benefit with the evidence from STEER that Wegovy offers not just weight loss but cardiovascular protection the case for choosing Wegovy through SheMed becomes even stronger.
You’re not just investing in weight management; you’re investing in heart health, future health, and a programme designed to keep you safe and supported every step of the way.
The Future of Health With SheMed
The STEER study is a reminder that the story of GLP-1s is still unfolding and it’s about so much more than weight loss. These medicines are changing how we think about obesity, cardiovascular health, and long-term wellbeing.
At SheMed, we’ll continue to keep you informed as new research emerges, but more importantly, we’ll keep showing you the bigger picture through your own results. With every blood test, every milestone, and every step forward, you’ll see how far you’ve come not just in weight, but in health.
Because at SheMed, you’re not just losing weight. You’re gaining health, protecting your future, and building the strongest version of you.
Wegovy has quickly become a key treatment option in obesity management, particularly for adults living with excess weight and health conditions linked to obesity.
With recent price increases for Mounjaro®, another GLP-1 medication, many patients and healthcare providers are now turning to Wegovy as a strong alternative.
Clinical research shows that Wegovy can deliver significant weight loss results, often comparable to those seen with Mounjaro, making it one of the most effective options currently available.
Recent news and clinical trial data reveal that higher doses of Wegovy specifically at 7.2 mg weekly, have led to average weight loss of around 21% in adults with obesity, with approximately one-third of participants achieving a weight loss of 25% or more over 72 weeks. This is notably greater than the 15% average weight loss seen at the standard 2.4 mg dose.
Latest Clinical Data on Higher Doses
The 2025 STEP UP phase 3b trial evaluated semaglutide at both 7.2 mg and 2.4 mg weekly doses versus placebo in people with obesity who did not have diabetes. The results indicated a clear dose-response effect:
Mean weight loss was 21% at 7.2 mg, compared to 17.5% at 2.4 mg, and much lower with placebo.
Specifically, 51% of those on 7.2 mg lost at least 20% of their body weight, and 33% achieved a reduction of 25% or more.
For 2.4 mg, 35% lost 20% or more, and 17% achieved 25% or greater weight loss.
Regulatory and Safety Considerations
Novo Nordisk has announced plans to seek regulatory approval for the higher 7.2 mg dose in the EU and other regions in late 2025.
Safety and tolerability of the 7.2 mg weekly dose were consistent with the known profile of semaglutide, with gastrointestinal side effects remaining most common, except for a low discontinuation rate for adverse effects (about 3%).
These findings extend the potential of Wegovy for people requiring greater degrees of weight loss, emphasising the dose-dependent effect of semaglutide GLP-1 therapy.
Comparing New findings with Mounjaro
At higher doses (7.2 mg), Wegovy has demonstrated weight loss outcomes that closely mirror those achieved with Mounjaro. Clinical data show an average 21% reduction in body weight over 72 weeks with Wegovy, with around half of patients reaching at least 20% weight loss. By comparison, Mounjaro studies report average reductions of up to 22–23% at higher doses over a similar treatment duration. While Wegovy’s 7.2 mg dose remains under regulatory review and is not yet standard practice, these findings highlight that patients considering a switch may be able to achieve results that are highly comparable to those seen with Mounjaro, offering another strong option in pharmacological obesity management.
Head-to-head style snapshot (72-week outcomes)
In conclusion, if you are considering switching from Mounjaro to Wegovy, now is an excellent opportunity. Wegovy offers a highly effective alternative for weight management with similar clinical results, and - importantly - comes at a considerably lower price, especially as Mounjaro prices are set to rise sharply in the UK from September 2025. Choosing Wegovy can help maintain your weight loss goals while making your treatment more affordable.
If you have any questions or need personalised advice about making the switch, please do not hesitate to contact the Shemed support team at support@shemed.com.
References
ClinicalTrials.gov. (2024, December 12). A research study to see how semaglutide helps people with excess weight, lose weight (STEP UP) (NCT05646706). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT05646706
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Wadden, T. A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
American Diabetes Association (ADA). (2025, June). STEP UP trial: Semaglutide 7.2 mg in adults with obesity without type 2 diabetes [Conference presentation]. ADA 85th Scientific Sessions, Chicago, IL. Retrieved from https://diabetesjournals.org/ (poster abstract ePoster 446-P).
Novo Nordisk. (2025, June 9). Semaglutide 7.2 mg shows ~21% weight loss at 72 weeks in STEP UP trial [Press release]. Retrieved from https://www.novonordisk.com/
Subscribe to our Newsletter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.